Literature DB >> 20718820

Lessons from the Salk polio vaccine: methods for and risks of rapid translation.

Justin E Juskewitch1, Carmen J Tapia, Anthony J Windebank.   

Abstract

The Salk inactivated poliovirus vaccine is one of the most rapid examples of bench-to-bedside translation in medicine. In the span of 6 years, the key basic lab discoveries facilitating the development of the vaccine were made, optimization and safety testing was completed in both animals and human volunteers, the largest clinical trial in history of 1.8 million children was conducted, and the results were released to an eagerly awaiting public. Such examples of rapid translation cannot only offer clues to what factors can successfully drive and accelerate the translational process but also what mistakes can occur (and thus should be avoided) during such a swift process. In this commentary, we explore the translational path of the Salk polio vaccine from the key basic science discoveries to the 1954 Field Trials and delve into the scientific and sociopolitical factors that aided in its rapid development. Moreover, we look at the Cutter and Wyeth incidents after the vaccine's approval and the errors that led to them.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20718820      PMCID: PMC2928990          DOI: 10.1111/j.1752-8062.2010.00205.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  17 in total

1.  Safety testing of poliomyelitis vaccine.

Authors:  P MEIER
Journal:  Science       Date:  1957-05-31       Impact factor: 47.728

2.  Studies in human subjects on active immunization against poliomyelitis. II. A practical means for inducing and maintaining antibody formation.

Authors:  J E SALK; P L BAZELEY; B L BENNETT; U KRECH; L J LEWIS; E N WARD; J S YOUNGNER
Journal:  Am J Public Health Nations Health       Date:  1954-08

3.  Recent studies on immunization against poliomyelitis.

Authors:  J E SALK
Journal:  Pediatrics       Date:  1953-11       Impact factor: 7.124

4.  Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress.

Authors:  J E SALK
Journal:  J Am Med Assoc       Date:  1953-03-28

5.  The Cutter incident, 50 years later.

Authors:  Paul A Offit
Journal:  N Engl J Med       Date:  2005-04-07       Impact factor: 91.245

6.  Patenting the Sun. Polio and the Salk Vaccine. Jane S. Smith. Morrow, New York, 1990. 413 pp. + plates. $22.95.

Authors:  P M Mazumdar
Journal:  Science       Date:  1990-11-09       Impact factor: 47.728

7.  III. SUMMARY OF ESTIMATES OF EFFECTIVENESS OF VACCINE.

Authors: 
Journal:  Am J Public Health Nations Health       Date:  1955-05

8.  Differentiation of types of poliomyelitis viruses; the grouping of 14 strains into three basic immunological types.

Authors:  D BODIAN; I M MORGAN; H A HOWE
Journal:  Am J Hyg       Date:  1949-03

9.  Managing Clinical Knowledge for Health Care Improvement.

Authors:  E A Balas; S A Boren
Journal:  Yearb Med Inform       Date:  2000

Review 10.  Poliovirus biology and pathogenesis.

Authors:  V R Racaniello; R Ren
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

View more
  7 in total

Review 1.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

Review 2.  Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.

Authors:  Julia L Hurwitz; Mattia Bonsignori
Journal:  Viral Immunol       Date:  2018-01-09       Impact factor: 2.257

Review 3.  Clinical trials in children.

Authors:  Pathma D Joseph; Jonathan C Craig; Patrina H Y Caldwell
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

4.  Case-Based Learning in Translational Biomedical Research Education: Providing Realistic and Adaptive Skills for Early-Career Scientists.

Authors:  Alexandra J Greenberg-Worisek; Katherine A Campbell; Eric W Klee; Nathan P Staff; Lisa A Schimmenti; Karen M Weavers; Stephen C Ekker; Anthony J Windebank
Journal:  Acad Med       Date:  2019-02       Impact factor: 6.893

5.  Optimizing Anti-Viral Vaccine Responses: Input from a Non-Specialist.

Authors:  Philip Serwer
Journal:  Antibiotics (Basel)       Date:  2020-05-15

6.  Exploration and Ethical Analysis of Open-label Pediatric Vaccine Trials in a Pandemic.

Authors:  Ian D Wolfe; Angira Patel; Larry K Kociolek; Asma Fazal; Ravi Jhaveri; John D Lantos
Journal:  Clin Ther       Date:  2021-05-24       Impact factor: 3.393

7.  The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines.

Authors:  Jeffrey E Harris
Journal:  Health Policy Technol       Date:  2022-03-21       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.